Bio Green Med Solution, Inc.

Regulatory Filings • Sep 11, 2023

CORRESP 1 filename1.htm

CYCLACEL PHARMACEUTICALS, INC.

200 Connell Drive, Suite 1500

Berkeley Heights, NJ 07922

VIA EDGAR

September 11, 2023

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Cyclacel Pharmaceuticals, Inc.

Registration Statement on Form S-3

Filed on September 1, 2023

File No. 333-274328

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. hereby requests that the effective date and time of the above-captioned registration statement be accelerated to Wednesday, September 13, 2023, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable.

If you have any questions regarding this request, please contact Joel Papernik of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. at (212) 692-6774.

Thank you very much.

Very truly yours,

CYCLACEL PHARMACEUTICALS, INC.

/s/ Paul McBarron
Paul McBarron
Chief Financial Officer
cc:	Securities and Exchange Commission
	Tyler Howes
	Cyclacel Pharmaceuticals, Inc.
	Spiro Rombotis, Chief Executive Officer
	Paul McBarron, Chief Financial Officer
	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	Joel Papernik, Esq.

Field: Page; Sequence: 1; Options: Last

Field: /Page